Delayed gentamicin elimination in patients with severe preeclampsia

Area of Science:

• Pharmacology
• Nephrology
• Obstetrics

Background:

• Gentamicin, an aminoglycoside antibiotic, is vital for treating polymicrobial infections.
• Preeclampsia presents with renal compromise, altered fluid balance, and potential pharmacokinetic changes.
• Understanding gentamicin handling in preeclampsia is crucial for effective treatment.

Purpose of the Study:

• To investigate the pharmacokinetic differences of gentamicin in normotensive, mild preeclamptic, and severe preeclamptic patients.
• To determine if altered renal function or volume of distribution primarily affects gentamicin elimination in preeclampsia.

Main Methods:

• Eighteen postpartum endometritis patients receiving gentamicin were grouped by preeclampsia status.
• Serum gentamicin levels were measured at 30, 150, and 450 minutes post-infusion.
• Pharmacokinetic parameters (half-life, clearance, volume of distribution) were calculated.

Main Results:

• Severe preeclamptic patients exhibited significantly longer gentamicin half-life (3.15 hours) and lower clearance (91.5 ml/min) compared to normotensive (2.38 hours, 135.9 ml/min) and mild preeclamptic (1.87 hours, 142 ml/min) groups.
• No significant differences in the volume of distribution were observed across groups.
• Correlation between elimination rate and distribution volume was high in normotensive but moderate in preeclamptic patients.

Conclusions:

• Altered renal function in severe preeclampsia is the primary driver of delayed gentamicin elimination.
• Changes in volume of distribution do not appear to significantly impact aminoglycoside pharmacokinetics in preeclampsia.
• This highlights the need for tailored gentamicin dosing strategies in preeclamptic patients.